Avanos Medical, Inc. Cash Flow Statement
AVNS / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Avanos Medical, Inc. generated $75M in operating cash flow and $43M in free cash flow in FY2025. Free cash flow margin was 6.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$72.9M | -$392.1M | -$61.8M | $50.5M | $6.3M | -$29.0M | -$45.9M | $57.5M | $79.3M | $39.8M | -$426.3M | $27.1M | $154.6M | $152.6M |
| Depreciation & Amortization | $38.9M | $45.5M | $46.1M | $47.7M | $38.3M | $42.9M | $36.9M | $33.5M | $59.5M | $65.2M | $65.4M | $85.4M | $69.2M | $57.6M |
| Operating Cash Flow | $74.7M | $100.7M | $32.4M | $90.9M | $87.3M | -$2.5M | -$74.5M | -$145.6M | $144.2M | $188.8M | $97.6M | $147.9M | $223.8M | $202.6M |
| Capital Expenditures | $31.6M | $17.8M | $17.8M | $19.3M | $21.0M | $20.2M | $50.6M | $49.1M | $43.2M | $29.1M | $70.4M | $78.5M | $49.0M | $40.8M |
| Free Cash Flow | $43.1M | $82.9M | $14.6M | $71.6M | $66.3M | -$22.7M | -$125.1M | -$194.7M | $101.0M | $159.7M | $27.2M | $69.4M | $174.8M | $161.8M |
| Share Buybacks | $3.3M | $12.8M | $19.1M | $45.5M | $11.5M | $900.0K | $3.6M | $900.0K | $2.5M | $900.0K | $1.0M | $0 | $0 | - |
| Dividends Paid | - | - | - | - | - | - | - | $0 | - | - | - | - | - | - |
| FCF Margin | 6.2% | 12.0% | 2.2% | 10.5% | 11.3% | -3.2% | -17.9% | -29.8% | 16.5% | 28.2% | 5.3% | 4.2% | 10.4% | 9.6% |